Cyclohexane

Cyclohexane

SCHEMBL2463063

C1CCCCC1.COc1cccc(OC)c1-c1ccccc1P

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 2/20 0.46
TOP1 P11387 1/20 0.44
ALDH1A1 P00352 4/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
MAPT P10636 3/20 0.44
APP P05067 1/20 0.44
KDM4E B2RXH2 1/20 0.44
USP2 O75604 1/20 0.44
DUSP3 P51452 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
CA7 P43166 2/20 0.43
CA9 Q16790 2/20 0.43
CA12 O43570 1/20 0.43
CA4 P22748 1/20 0.43
CA14 Q9ULX7 1/20 0.43
HTR1A P08908 2/20 0.42
DRD2 P14416 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL365363 0.94 TOP1 (0.48) HTR7TOP1ALDH1A1MEN1KMT2A
SCHEMBL21820014 0.87 HTR2C (0.43) HTR7MEN1KMT2AUSP2HTR1A
SCHEMBL14810064 0.86 HTR1A (0.42) HTR7TOP1ALDH1A1MEN1KMT2A
Toluene SCHEMBL27963742 0.86 TOP1 (0.42) HTR7TOP1ALDH1A1MEN1KMT2A
SCHEMBL10177350 0.84 TOP1 (0.43) HTR7TOP1ALDH1A1MEN1KMT2A
SCHEMBL17529730 0.82 TOP1 (0.48) HTR7TOP1ALDH1A1MEN1KMT2A
SCHEMBL29174505 0.82 APP (0.59) HTR7TOP1ALDH1A1MEN1KMT2A
SCHEMBL30721042 0.80 CA1 (0.41) HTR7TOP1ALDH1A1MEN1KMT2A
SCHEMBL366917 0.80 ALDH1A1 (0.44) HTR7TOP1ALDH1A1MEN1KMT2A
SCHEMBL13144640 0.80 CA1 (0.52) TOP1ALDH1A1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109096274-A It can be used for treating the aryl-linking compound of human tumor, neurology and amynologic disease 比奥根MA公司 2018-12-28 CN disclosed
CN-108947913-A It can be used for treating the aryl-linking compound of human tumor, neurology and amynologic disease 比奥根MA公司 2018-12-07 CN disclosed
CN-106459002-B Biaryl compounds useful in the treatment of human oncological, neurological and immunological diseases 比奥根MA公司 2018-08-21 CN disclosed
CN-105308032-B Novel triazole derivatives 拜耳作物科学股份公司 2017-05-24 CN disclosed
CN-106459002-A Biaryl compounds useful in the treatment of human oncological, neurological and immunological diseases 比奥根MA公司 2017-02-22 CN disclosed
CN-105308032-A Novel triazole derivatives BAYER CROPSCIENCE AG 2016-02-03 CN disclosed
CN-103108866-B cyclohexane derivative compound DAIICHI SANKYO Co.,Ltd. (JP) 2015-09-09 CN disclosed
US-9130233-B2 Metal complex, modified compound thereof and useful compound thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-09-08 US disclosed
US-9051255-B2 Piperazinyl cyclohexane compounds as GPR38 agonists DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-06-09 US disclosed
US-20140221392-A1 CYCLOHEXANE DERIVATIVE COMPOUND DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-08-07 US disclosed
US-20130289048-A1 CYCLOHEXANE DERIVATIVE COMPOUND DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-10-31 US disclosed
US-8536338-B2 Compounds for the treatment of hepatitis C BRISTOL-MYERS SQUIBB COMPANY (US) 2013-09-17 US disclosed
US-20130210615-A1 METAL COMPLEX, MODIFIED COMPOUND THEREOF AND USEFUL COMPOUND THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-08-15 US disclosed
EP-2623492-A1 CYCLOHEXANE DERIVATIVE COMPOUND DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-08-07 EP disclosed
EP-2545050-A1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C Bristol-Myers Squibb Company (US) 2013-01-16 EP disclosed
US-20120232099-A1 Compounds for the Treatment of Hepatitis C BRISTOL-MYERS SQUIBB COMPANY 2012-09-13 US disclosed
US-8198449-B2 Compounds for the treatment of hepatitis C BRISTOL-MYERS SQUIBB COMPANY (US) 2012-06-12 US disclosed
WO-2011112186-A1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY (US) 2011-09-15 WO disclosed
US-20100184800-A1 Compounds for the Treatment of Hepatitis C BRISTOL-MYERS SQUIBB COMPANY 2010-07-22 US disclosed
US-20100063068-A1 Compounds for the Treatment of Hepatitis C BRISTOL-MYERS SQUIBB COMPANY 2010-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221392-A1 CYCLOHEXANE DERIVATIVE COMPOUND HRH2, CBR1, HRH4 HTR7 1880/4885TOP1 2593/4885ALDH1A1 1561/4885
US-20100063068-A1 Compounds for the Treatment of Hepatitis C HAVCR2, HCCS, SLC10A1 HTR7 3802/4885TOP1 1476/4885ALDH1A1 447/4885
US-20100184800-A1 Compounds for the Treatment of Hepatitis C HAVCR2, HCCS, SLC10A1 HTR7 3802/4885TOP1 1476/4885ALDH1A1 447/4885
US-20130210615-A1 METAL COMPLEX, MODIFIED COMPOUND THEREOF AND USEFUL COMPOUND THEREOF C5, PRMT1, C1QBP HTR7 4116/4885TOP1 4278/4885ALDH1A1 1546/4885
US-20120232099-A1 Compounds for the Treatment of Hepatitis C HAVCR2, HCCS, SLC10A1 HTR7 3802/4885TOP1 1476/4885ALDH1A1 447/4885
US-20130289048-A1 CYCLOHEXANE DERIVATIVE COMPOUND HRH2, CBR1, HRH4 HTR7 1880/4885TOP1 2593/4885ALDH1A1 1561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.